DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,129 filers reported holding DANAHER CORPORATION in Q1 2017. The put-call ratio across all filers is 0.41 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $2,584,000 | -18.8% | 12,000 | -33.3% | 0.47% | -21.2% |
| Q2 2020 | $3,183,000 | +9.5% | 18,000 | -14.3% | 0.60% | -6.7% |
| Q1 2020 | $2,907,000 | -9.8% | 21,000 | 0.0% | 0.64% | +27.9% |
| Q4 2019 | $3,223,000 | +6.3% | 21,000 | 0.0% | 0.50% | +5.3% |
| Q3 2019 | $3,033,000 | +1.1% | 21,000 | 0.0% | 0.47% | -2.5% |
| Q2 2019 | $3,001,000 | -12.6% | 21,000 | -19.2% | 0.49% | -14.1% |
| Q1 2019 | $3,433,000 | +23.3% | 26,000 | -3.7% | 0.57% | +24.4% |
| Q4 2018 | $2,784,000 | -48.8% | 27,000 | -46.0% | 0.46% | -37.4% |
| Q3 2018 | $5,433,000 | +7.9% | 50,000 | -2.0% | 0.73% | +9.0% |
| Q2 2018 | $5,033,000 | -6.5% | 51,000 | -7.3% | 0.67% | -2.6% |
| Q1 2018 | $5,385,000 | +7.4% | 55,000 | +1.9% | 0.68% | +7.4% |
| Q4 2017 | $5,012,000 | -7.3% | 54,000 | -14.3% | 0.64% | -8.5% |
| Q3 2017 | $5,404,000 | -1.5% | 63,000 | -3.1% | 0.70% | +0.1% |
| Q2 2017 | $5,485,000 | -1.3% | 65,000 | 0.0% | 0.70% | -2.2% |
| Q1 2017 | $5,559,000 | +29.9% | 65,000 | +18.2% | 0.71% | +29.0% |
| Q4 2016 | $4,281,000 | +16.2% | 55,000 | +17.0% | 0.55% | +13.8% |
| Q3 2016 | $3,684,000 | – | 47,000 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |